Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)

Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or t...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 134; no. 24; p. 1918
Main Authors:	Michael Gibson, C, Korjian, Serge, Tricoci, Pierluigi, Daaboul, Yazan, Yee, Megan, Jain, Purva, Alexander, John H, Steg, P Gabriel, Lincoff, A Michael, Kastelein, John J P, Mehran, Roxana, D'Andrea, Denise M, Deckelbaum, Lawrence I, Merkely, Bela, Zarebinski, Maciej, Ophuis, Ton Oude, Harrington, Robert A
Format:	Journal Article
Language:	English
Published:	United States 13.12.2016
Subjects:	Acute Disease Adult Aged Alanine Transaminase - blood Bilirubin - blood Biomarkers - blood Creatinine - blood Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Half-Life Hemorrhage - etiology Humans Lipoproteins, HDL - adverse effects Lipoproteins, HDL - pharmacokinetics Lipoproteins, HDL - therapeutic use Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - pathology Placebo Effect Proportional Hazards Models Treatment Outcome alipoprotein A-I myocardial infarction
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!